Company news

Share this article:
Thomson Scientific, part of The Thomson Corporation, launched its Citation Impact Forum, an online forum promoting scholarly discussion about all facets of citation-based research evaluation. The Citation Impact Forum will feature interviews with and commentary from industry leaders - bibliometricians, researchers and publishers - about scholarly evaluation.  By becoming a registered member of the forum, users have the added ability to join invitation only forums where they can participate in discussions by sharing their own thoughts with other members.  Registered members can also recommend future forum discussion topics. Thomson Scientific will also use the Forum to address - or to clarify -- inaccuracies and common misinterpretations circulating among the scientific community, printed in journals, blogs and other forums.  Thomson Scientific's Citation Impact Forum, can be found by visiting: scientific.thomson.com/citationimpactforum/.

Bedford Laboratories, a division of Ben Venue Laboratories Inc., announced the acquisition of Cafcit (caffeine citrate) Injection and Cafcit (caffeine citrate) Oral Solution from Mead Johnson & Company. Bedford Laboratories is now the reference listed drug holder. Cafcit (caffeine citrate) is indicated for the short-term treatment of apnea in premature infants between 28 and <33 weeks gestational age. Ben Venue Laboratories is a subsidiary of Boehringer Ingelheim.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.